Altimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag for Pemvidutide in MASH Trial

Simply Wall St.01-26

Altimmune recently received FDA Breakthrough Therapy Designation for its investigational drug pemvidutide after mid‑stage data showed significant MASH resolution, and the company plans a 52‑week late‑...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606264764?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-26 07:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606264764","market":"nz","top_or_hot":-1,"title":"Altimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag for Pemvidutide in MASH Trial","media":"Simply Wall St.","content":"<div>\n<p>Altimmune recently received FDA Breakthrough Therapy Designation for its investigational drug pemvidutide after mid‑stage data showed significant MASH resolution, and the company plans a 52‑week late‑...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alt/altimmune/news/altimmune-alt-is-up-297-after-fda-breakthrough-tag-for-pemvi\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Altimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag for Pemvidutide in MASH Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAltimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag for Pemvidutide in MASH Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-26 07:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alt/altimmune/news/altimmune-alt-is-up-297-after-fda-breakthrough-tag-for-pemvi><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Altimmune recently received FDA Breakthrough Therapy Designation for its investigational drug pemvidutide after mid‑stage data showed significant MASH resolution, and the company plans a 52‑week late‑...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alt/altimmune/news/altimmune-alt-is-up-297-after-fda-breakthrough-tag-for-pemvi\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4599","symbol_name":"减肥药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alt/altimmune/news/altimmune-alt-is-up-297-after-fda-breakthrough-tag-for-pemvi","article_id":"2606264764","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alt/altimmune/news/altimmune-alt-is-up-297-after-fda-breakthrough-tag-for-pemvi","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2606264764","pubTimestamp":1769382973,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Altimmune recently received FDA Breakthrough Therapy Designation for its investigational drug pemvidutide after mid‑stage data showed significant MASH resolution, and the company plans a 52‑week late‑stage trial to test multiple doses.\nThis designation could shorten regulatory timelines and enhance pemvidutide’s profile in the competitive MASH treatment landscape, potentially reshaping Altimmune’s long‑term product mix and risk profile.\nNext, we’ll examine how pemvidutide’s Breakthrough...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4599":"减肥药","ALT":"Altimmune, Inc.","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","BK4139":"生物科技"},"translate_title":"FDA在MASH试验中突破Pemvidutide标签后，Altimmune(ALT)股价上涨29.7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALT":1.5},"content_text":"Altimmune recently received FDA Breakthrough Therapy Designation for its investigational drug pemvidutide after mid‑stage data showed significant MASH resolution, and the company plans a 52‑week late‑stage trial to test multiple doses. This designation could shorten regulatory timelines and enhance pemvidutide’s profile in the competitive MASH treatment landscape, potentially reshaping Altimmune’s long‑term product mix and risk profile. Next, we’ll examine how pemvidutide’s Breakthrough Therapy Designation influences Altimmune’s investment narrative and the perceived strength of its pipeline. Find companies with promising cash flow potential yet trading below their fair value.AdvertisementWhat Is Altimmune's Investment Narrative?To own Altimmune today, you have to believe that pemvidutide can evolve from a promising Phase 2b asset into a commercially relevant MASH, AUD and ALD franchise, without the support of meaningful current revenue. The new Breakthrough Therapy Designation sharpens that thesis by potentially pulling forward timelines for MASH and lifting confidence in the overall program, which helps explain the sharp share price rebound after a difficult multi‑year run. In the near term, the key catalyst shifts even more clearly to the planned 52‑week late‑stage MASH trial design and execution, alongside upcoming AUD data, while funding needs and past dilution remain central risks. If Breakthrough status ultimately translates into cleaner trial negotiation with the FDA, the risk balance could modestly improve, but clinical and regulatory uncertainty still dominates. However, there is a funding and dilution risk here that investors should not overlook.\n\nAltimmune's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Exploring Other PerspectivesALT 1-Year Stock Price Chart Six fair value views from the Simply Wall St Community span from almost zero to US$17.88 per share, underscoring very different expectations around pemvidutide. Against that backdrop, the fresh Breakthrough Therapy Designation puts even more weight on upcoming trial design and financing decisions, which could influence how those diverse expectations evolve from here.Explore 6 other fair value estimates on Altimmune - why the stock might be worth less than half the current price!Build Your Own Altimmune NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Altimmune research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.Our free Altimmune research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Altimmune's overall financial health at a glance.Contemplating Other Strategies?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 32 best rare earth metal stocks of the very few that mine this essential strategic resource.AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606264764","isCrawlerRequest":true}